1. Clinical Trial Outcomes
Table 6: European Cessation Trial (2024)
| Intervention | 1-Year Abstinence | Craving Reduction |
|---|---|---|
| Standard NRT | 19% | 41% |
| AI-Powered DBS Implant | 63% | 88% |
| VR Exposure Therapy | 28% | 52% |
| Source: New England Journal of Medicine 2025 |
Technology Breakdown
MIT’s device combines:
- Insular cortex microstimulation (200Hz pulses during craving episodes)
- Real-time dopamine tracking (fiber photonics detect ventral tegmental area activity)
- Machine learning prediction (93% accuracy in anticipating relapse 6hrs pre-onset)
Lead researcher Dr. Emilia Wagner stated:
“Our neural interface reduced cigarette-related hippocampal engram reactivation by 74% in primates – human trials show similar promise.”